A salient characteristic of the prion diseases-including Creutzfeldt-Jakob disease and bovine spongiform encephalopathy in cattle-is an extended asymptomatic incubation period followed by a rapid and often fatal clinical phase. We present a kinetic model of progression of infection based upon the existence of a bottleneck in the natural protein pathways within the cell. The model can reconcile the different time-scales of the pre-clinical and clinical phases, and is able to account for the dependency of the duration of the incubation period on several important governing factors, including the inoculum size, the phenotype of the host, and the phenotype of the pathogenic form of the prion protein. Our results suggest that saturation events-first of the rate of pathogenic transformation (an auto-catalysis ceiling), and subsequently of the bottleneck in the protein pathways-could be fundamental in determining the dynamics of infection.
The prion diseases (spongiform encephalopathies) are a family of neurodegenerative disorders associated with accumulation of a protease-resistant isoform (PrP Sc ) of the cellular prion protein (PrP C ) (Prusiner et al., 1991) . The protease-resistant isoform is able to act as a transmissible pathogen with a prolonged incubation period, but unlike bacteria, viruses or viroids, the prion appears able to propagate without the involvement of nucleic acids (Prusiner, 1982; Alper, 1993) . The prion diseases have been transmitted to numerous vertebrate species, in which the ease of transmission and length of the incubation period are related to key substitutions in the prion gene of the host. To appreciate the various genetic and strain-dependent factors that have been identified as determinants of latency duration requires an understanding of the mechanisms underlying incubation. Unusually for a pathogen, the prion does not elicit a strong immune reaction (Alper, 1992; Berg, 1994) presumably a consequence of its similarity to the host protein-and so the incubation period cannot be accounted for by immune mechanisms. We present a model of prion disease incubation that relates molecular data on intracellular prion kinetics to clinical data on prion disease aetiology. The model is based on the existence of a kinetic bottleneck in the cellular pathways of protein turnover, which we suggest could be identified with a putative receptor for PrP C , that would place a restriction on the availability of cell-surface binding sites for the prion protein. Before describing the model and its dynamic behaviour we review some of the relevant experimetal observations relating to the prion diseases.
    
Prion protein exists normally in a protease-sensitive state bound to the surface of nerve cells by a glycoinositol phospholipid (GPI) anchor. Most PrP C is catabolized with a half life of approximately 3-6 hr, whereas PrP Sc shows next to zero turnover, and can consequently build up forming amyloid plaques (Prusiner et al., 1983; DeArmond et al., 1985) . A conformational change is thought to represent the principal difference between the cellular isoform and the protease-resitant, pathogenic isoform. The process of conversion has not yet been fully characterized (Huang et al., 1996) , although it is known that the efficiency of conversion is mediated by differences in the protein sequences, such that infectious transmission is prevented or delayed between certain species. Following translation and conjugation to the GPI anchor, the prion protein cycles between the cell surface and endocytic compartments within the cell (Taraboulos et al., 1992) . Endocytosis proceeds through clathrin coated pits in which the secondary and tertiary structure of the protein has been conjectured to engage the endocytic machinery directly, a mechanism which has led to the suggestion for the existence of a putative PrP C receptor (Harris et al., 1996) . Once formed, PrP Sc appears to accumulate in lysosomes within the cell (Caughey & Raymond, 1991; McKinley et al., 1991) .
The manner in which the spongiform diseases are acquired are classified into inherited, sporadic and infectious categories. The latter two are closer to operational distinctions than to unique processes of pathogenesis. In the inherited cases, pathogenic mutations are recognized which cosegregate with disease and in which the identification of a mutation will often allow for a diagnosis of the disease. Sporadic cases are identified by the absence of a family history and by ruling out obvious iatrogenic contamination (accidental inoculation during medical procedures). These cases usually occur as sporadic Creutzfeldt-Jakob disease (CJD), and could result from some as of yet unidentified environmental factors (Brown, 1996) , or come about through a process of genetic senescence. Recent evidence suggests that some prion genotypes are more likely to manifest sporadic illness than others (Collinge & Palmer, 1994) . Infectious transmission of the pathogenic prion is identified in the absence of a family history and any known disease-causing mutation. In the human population infectious transmission has either been via corneal or dura mater grafts, through various pituitary-derived hormone therapies in which the hormone had been obtained from diseased cadavers (Collinge & Palmer, 1994) , or-as was the case with kuru-transmitted through ritual cannibalism (Alpers, 1987) . In many other mammal species a growing body of evidence attests to the efficiency of infectious transmission: numerous experimental transmissions of scrapie via oral, sub-cutaneous and intra-cerebral routes have led to the development of this disease in mice, hamsters, cats, goats, cattle and primates (Fraser, 1993) .
Spongiform encephalopathies exhibit a prolonged interval between initial infection and the appearance of clinical disease. In the case of iatrogenic  this interval reaches a minimum of 2 years with infected dura mater transplants and has a mean of around 12 years following peripheral infection with pituitary derived hormones . Following experimental infection of scrapie into mice, the incubation period is observed to depend on the prion genotype at codons 108 and 189, and ranges from around 127 days to 376 days (Carlson et al., 1994) . Infection of  into mice results in disease between 300 and 700 days depending on prion genotype (Bruce et al., 1994) . The incubation period is therefore highly variable between species and depends strongly on the host genotype and the site of inoculation. The genetically determined level of PrP C production is negatively correlated with incubation time (Weissman et al., 1993) : mice devoid of prion protein (PrP-p-0/0) are resistant to scrapie infection, mice heterozygous for PrP C gene ablation (PrP-p-0/+) are partially protected, while mice homozygous for PrP C (PrP-p+/ +) remain highly susceptible.
A Kinetic Model of Disease Latency
The time between infection and death can be thought of as being made up of a number of phases, T death = T 1 + T 2 + T 3 + T 4 . The first contribution, T 1 , is from delays attending peripheral routes of inoculation; T 2 is a dynamical delay that we demonstrate using our model; T 3 starts when significant levels of PrP Sc become detectable in vivo; T 4 starts when clinical symptoms first appear, and ends at time of death. Delays attending peripheral routes of infection are not considered in our model. While these are undoubtably important in extending disease latency, little is known about the diffusion of prion protein; hence we choose to concentrate on intracellular dynamics, showing how this phase alone can produce paradoxically long latencies. We also do not explicitly consider the final symptomatic phase. This is because it is short in comparison with the overall latency, and is therefore less informative with respect to the dependency of latency duration on genetic and strain dependent factors.
Any model for the dynamics of prion disease pathogenesis must be able to capture two unusual characteristic features of certain strain-species combinations: the existence of a lower limit on the duration of the incubation period following intracerebral inoculation; and in many cases an abrupt rather than gradual onset to the clinical phase. The former is incompatible with a simple, exponential increase in PrP Sc concentration, and implies that at least some part of the incubation process must be non-exponential, probably linear, in form. The latter could arise for various reasons, including a bistable kinetic system, a genetic switch, or the reservoir of transformable PrP C increasing with time. A bistable system (one with two stable states-one normal, one pathological) relies on the assumption that PrP
Sc is naturally present in all animals, albeit at very low concentrations in healthy individuals, and involves perturbations initiated by inoculation with PrP Sc acting to switch the system from the healthy to the pathogenic state. Such a system has been looked at by Laurent (1996) and by Eigen (1996) , who in addition
considered how a nucleation model could provoke sudden onset, but suffers a serious drawback in that it ''seems to contradict the observation on incubation times up to several years in humans, and many hundred days in mice' ' (Laurent, 1996, p. 39) . The presence of a genetic switch cannot be entirely ruled out at present. For there to be an increase in the concentration of ''susceptible'' protein requires there either to be an increasing rate of production (unlikely, given that PrP mRNA production is constant), or for there to be some bottleneck in the pathways of normal protein turnover which becomes blocked once a critical protein concentration is exceeded. The model that we set out below demonstrates how this last scenario is compatible with many important features of the prion diseases. We ascribe the bottleneck to the presence of a putative cell-surface receptor: this would seem the most natural choice, although other causes of bottlenecks yielding the same general behaviour cannot be ruled out. We also stress that the model is generic with respect to the mechanism of prion propagation: it does not depend, explicitly upon an informational molecule as in the ''Prusiner mechanism'' or a nucleation model as first suggested by Griffith (1967) .
 
To describe the kinetics of prion diseases a mathematical model is used in which we track the dynamics of the concentrations of protease-sensitive prion protein, PrP C , bound to cell surfaces [B(t)] and internalized [C(t)], and the protease-resistant isoform, PrP Sc , also bound [R(t)] and internal [S(t)]. The model consists of a system of four ordinary differential equations which reflect the essential features of intracellular prion life history (summarized in Fig. 1 ):
The mathematical formulation is not explicitly multicellular and does not include terms to account for intercellular movement of the proteins. This is because we are considering how intracellular dynamics can impose a lower limit on latency duration. Furthermore, the distribution of PrP Sc is often more widespread than that of the histopathological lesions (Prachi et al., 1995) , and disease has been observed with a single focus of spongiform change (Kornfeld & Seelinger, 1994) . These observations suggest that the different magnitudes and time-scales of the intracellular vs. intercellular events cause spatial effects resulting from protein diffusion to remain small until the intracellular latent period, T 2 , comes to an end.
The equations account for three types of process:
(1) Association/dissociation of the prions to the appropriate cell-surface receptors. The parameter X represents the total possible binding sites, j 1 is the coefficient of association (rate of passage along secretory pathway), and j 2 the coefficient of dissociation (rate of passage along endocytic pathway). The quantity X − B − R is the number of unused sites. Similarly k 1 and k 2 are the relevant coefficients to and from the cell surface for the kinetics of the PrP Sc . The passage along the pathways occurs on a time-scale of the order of a few hours (Harris et al., 1996) which is much faster than the time-scale of the infective process: the model parameters must be chosen accordingly.
(2) Conformational transformation of PrP C by PrP Sc . This is thought to involve a post-translational event (Basler et al., 1986) along an endocytic pathway while bound to cytoplasmic vesicles within the cell (Borchelt et al., 1992 (Oesch et al., 1985; Kretzschmar et al., 1986) , and so in the model the healthy host protein is assumed to be produced at a constant rate e within the cell, and to decay with rate coefficient d; the protease-resistant isoform decays with coefficient a, where a d. The break-down of PrP C , which is believed to occur along the endocytic pathway, only occurs subsequent to passage via the cell surface, and so the decay term is included in the dB/dt equation.
 
There are three important features of the model (i) the pathogenic isoform transforms the host protein when intracellular rather than when attached to the cell surface binding sites, so that the proteins available for transformation (''susceptibles'', by analogy with epidemiology) only includes the internal membrane PrP C ; (ii) there is an upper limit on the auto-catalytic properties of PrP Sc , such as might be imposed by a ''protein X' ' (Telling et al., 1995) , a specific macromolecule thought to participate in PrP Sc folding; (iii) there are a restricted number of receptor sites. If these sites become saturated, then, because break-down of PrP C only occurs subsequent to passage via the cell surface, there will be a build-up of internal protein unable to bind to the surface. In healthy subjects there is a stable balance between production and degradation of PrP C , and the receptor sites normally never become saturated. In contrast, the PrP Sc isoform is protease-resistant and so will gradually accumulate until all of the cell-surface receptor sites are filled.
The essential features of the behaviour may be understood heuristically as follows: Initially the internal membrane levels of both PrP C and PrP Sc are small, and so the net transformation rate is low. At the start of infection the rate of transformation is proportional to the concentration of internal PrP Sc (S), and so the total PrP Sc increases exponentially. After a while, the magnitude of S reaches a level at which the autocatalytic effect of the PrP Sc reaches its limit, after which the PrP Sc levels increase linearly with time. We assume this transition occurs when S is still small, so that the concentration of internal PrP C (C) undergoes negligible change during this period. Eventually, however, the increase in cell-surface PrP Sc leads to the saturation of the available receptor sites. Subsequent to saturation the levels of internal PrP C and PrP Sc both build up, as the proteins are now unable to find free receptors upon which to bind. The increased density of the susceptible protein means that the ceiling on PrP Sc propagation is raised, so that the (density-dependent) net rate of transformation is enhanced, leading to clinically significant levels of accumulation.
We identify the slow phase prior to saturation as a major part of the sub-clinical incubation period, and the fast phase following saturation as contributing to the suddenness of the fulminant clinical phase. The dynamic delay is further composed of two components-the time before the auto-catalysis ceiling is reached, and the time thereafter. The dynamics of our model are illustrated by the computer simulation shown in Fig. 2 : it is only after saturation of the cell surface receptors, which may take many years in humans, that the concentration of intracellular prion protein can become sufficient for clinically significant propagation of the pathogenic PrP Sc . [Note on parameter values: Experimental measurements of parameters are for the most part not available, and so the choice of values used in the simulations is to some extent arbitrary. Nonetheless the following restrictions apply-the rate of passage along secretory and endocytic pathways should be of the order of a few hours; the coefficient of infectivity must be small, such that, during the latency period, the rate of infection is much slower than the rate of protein turnover; the decay coefficient of the protease-resistant isoform is by definition large relative to the protease-sensitive isoform; concentrations can be scaled relative to the total receptor number. Actual parameter values will vary widely amongst different species/strain combinations. We use slightly different parameter sets in Figs 2 and 3 so as to aid visualisation of the respective processes under discussion.]
Determinants of Latency Duration
Under our hypothesis, the dynamic component of latency duration (T 2 + T 3 ) depends on three interacting processes: the time taken for the PrP Sc to achieve its auto-catalysis ceiling, the time until receptor saturation, and the time required for the PrP Sc to accumulate thereafter to clinically significant levels. Consideration of these three components allows us to predict the ways in which different phenotypic and contextual factors influence latency. (The full disease duration will depend also on delays from any peripheral route (T 1 ), and on the length of the symptomatic phase (T 4 ). 
 
Different host genotypes may show phenotypic variation in the rate of PrP C production, the rate of PrP C removal, the number of cell-surface receptor sites, and the rate of PrP C -receptor association and dissociation. The rate of PrP C removal (parameter d) determines the pre-infection equilibrium, and thereby influences incubation times in two waysvia the density of ''susceptible'' protein initially available for transformation, and indirectly via the number of receptor sites which are unused at equilibrium and that must be bound to achieve saturation. The rate of PrP C production (e) also determines the pre-infection equilibrium, but in addition has a direct effect by controlling the supply of new susceptibles required for continued PrP Sc propagation both before and subsequent to saturation. Without the presence of the host protein there can be no spread of the pathogenic isoform. The total number of cell-surface receptors (X) has a direct effect, since all of the receptors must be bound prior to saturation: short incubation periods could be a consequence of hosts with abnormally low numbers of receptors. Changes in the rate of trafficking along the secretory and endocytic pathways (j 1 , j 2 ), which influences the initial ratio of internal/surface PrP C , might result from variation in either the prion protein or ancillary proteins assisting in transport.
PP S 
The pathogenic isoform is characterized as being protease-resistant, and the negligible rate of PrP Sc removal (a d) is important in allowing the gradual build-up of PrP Sc that leads to saturation. Different strains may have different transforming potential (n), which is a strong determinant of latency duration. There is also likely to be variation between PrP Sc strains in the concentration that must accumulate (subsequent to saturation) to achieve host morbidity. This will influence the duration of the clinical phase of disease. 

Both the size and the site of inoculation affect incubation period. Dose-response curves typically exhibit a lower limit on the duration of the incubation period (Robinson et al., 1990; Scott, 1993; . In our model a lower limit on the brevity of incubation duration can occur because of the limited rate of PrP Sc propagation imposed once the auto-catalysis ceiling is reached. The inoculum size affects the time prior to the ceiling, but has negligible influence on the rate of disease progression thereafter. Figure 3 gives an example dose-response curve from our computer simulations. The magnitude of the lower limit can vary between hosts and between strains, depending on the concentration of PrP Sc required to achieve the auto-catalysis ceiling (f ). In heritable human spongiform encephalopathies, for example, disease associated with homozygosity at codon 129 has a minimum incubation period of 50 years in FFI and of 31 years in CJD (Gambetti, 1996) .
Inherited and Sporadic Disease
In the inherited human forms of prion disease there are characteristic mutations along the gene of the prion protein [mutations at codon 178 for kindreds suffering from fatal familial insomnia (Medori et al., 1992) , at codon 200 for CJD amongst the Libyan Jews (Goldfarb et al., 1992) , and at codon 102 for victims of Gerstmann-Straussler, Scheinker syndrome (Hsiao et al., 1992) ]. If the host protein thereby acquires an abnormally low decay rate, as is true for infectious forms of PrP Sc , then it is possible for the protein to gradually accumulate over the course of a lifetime. As with the infectious kinetics this would lead to saturation of the PrP C receptor and consequent ''stock-piling'' of PrP Sc within compartments in the cell. The provenance of sporadic disease is unknown, but could be a consequence of somatic mutations occurring during ontogeny. This can be thought of as the infectious case with a very low volume of inoculum, implying that incubation periods of sporadic disease should be relatively lengthy.
Discussion
We have shown that a bottleneck in the intracellular cycling pathways of prion protein is capable of producing the characteristic abrupt onset associated with the spongiform encephalopathies. A cell-surface receptor could be the cause of such a bottleneck and is consistent with the findings of Harris et al. (1996) , who postulate the existence of a putative cell-surface PrP C receptor based upon molecular biological data. The behaviour of interest is revealed without recourse to inclusion of the details of pathophysiology-the model can determine the factors governing the duration of the incubation period and eliminate those processes which, although essential pathologically, are inessential dynamically.
The multiphase structure of disease incubationprolonged asymptomatic, subclinical phase and abrupt clinical phase-requires some threshold in conversion of the protein to be breached, following a period of stasis in which the immune system has played little or no part. We suggest that this threshold is a consequence of the saturation of the putative prion receptors by the low decay rate, pathogenic isoform (PrP Sc ). There then follows an auto-catalytic propagation of PrP Sc within the cell, proportional to the rate of host protein (PrP C ) production. This is in keeping with the results of experiments in which the appearance of intracellular PrP Sc is blocked when protein is regularly cleaved from the cell surface, presumably forestalling saturation (Caughey & Raymond, 1991) .
We suggested that the existence of a minimum latency duration may be attributable to an upper limit on the transformation rate. Whilst such an upper limit F. 3. Dose-response curves. Simulations of the model can be used to predict dose-response curves. The conjectured ceiling on the autocatalysis of PrP C 4PrP
Sc transformation implies a possible restriction on the brevity of the incubation period, the value of the lower limit being strain-dependent. In the example shown we have chosen the parameter values to give a minimum latency, except for unbiologically high doses, of approximately 150 days. This is comparable with experimental data on intracerebrally scrapie inoculated C57B1 genotype mice (Scott, 1993) . Note that a simple exponential accumulation of PrP Sc would imply a straight line through the origin; and thus would be inconsistent with an effective minimum latency. Parameter values: j1 = kl = 50.0 days must exist, it is not possible at present to determine whether this is the source of the rate determining step in disease progression. An alternative hypothesis is the replication-site hypothesis, which explains disease latency as the result of delays attending peripheral routes of pathogenesis, for example in the spleen combined with competition for a PrP C replication site (Dickinson & Outram, 1979) . The two are not exclusive, and the total incubation time is going to be the sum of both peripheral pathogenesis and kinetic processes in the central nervous system. There are, however, two lines of evidence which emphasise the importance of the intracellular kinetics: following a splenectomy (in which the spleen is removed) there is no reduction in the incubation period of certain strains of scrapie infection, suggesting that this compartment need not hinder the spread of disease (Kimberlin & Walker, 1989) (Sakaguchi et al., 1995) because of possible strain specific transformation rates (n i ) in which the structural interaction with the host protein differs according to the sequence of infecting protein strain i. Studies using serial 10-fold dilutions show decreasing incubation periods with increasing dosage, but only down to a lower limit (Prusiner et al., 1990 ), which our model accounts for by assuming a ceiling on the auto-catalytic properties of the PrP Sc . This is a consequence of restricted access to the unconverted PrP C . Although the model can mimic the lower limit on incubation duration exhibited by dose-response curves, it does not provide information as to the biological mechanism for the auto-catalysis ceiling. This might come about through interactions with ''protein X'': this unidentified agent is thought to act as a ''scaffold'' or chaperone protein participating in the folding of PrP Sc . The model allows identification of several ways in which the incubation period could become shortened: (i) the host produces particularly high levels of PrP C , which causes an enhanced rate of conversion throughout the disease; (ii) the host cells have an abnormally low number of protein binding sites, which causes saturation to be achieved more rapidly; (iii) a putative new strain of PrP Sc is able to convert PrP C at any point in the production cycle, not exclusively during endocytosis; or (iv) a putative new strain of PrP Sc can enter previously uninfected cell populations with few binding sites. These last two variations would reduce the incubation period dramatically, and might contribute to the species barrier effect, in which the likelihood of transmission of a new strain to the non-host species will depend on specific affinities between the amino acid sequence of the new strain and the host prion gene (Krakauer et al., 1996) . A therapeutic implication of the model is that clinical onset should be impeded by cleaving protein from the cell surface, as in the experiments of Caughey & Raymond (1991) . This not only reduces the PrP C available for transformation but, more importantly, prevents progression to clinical disease by delaying saturation of the cell surface receptors. Our results suggest that preferentially targeting the PrP Sc rather than the PrP C should maintain similar therapeutic benefits yet without risking loss of possible function (Sakaguchi et al., 1996; Tobler et al., 1996) .
Appreciation of the dynamical aspects of pathogenesis has proved to be illuminating in our understanding of the mechanisms involved in a number of other slow diseases (e.g. Nowak & Bangham, 1996; Payne et al., 1996) . The novel mechanism for prion disease incubation that we propose here uses a combination of data on molecular kinetics and data on disease aetiology in order to provide a framework for interpreting the observed variation in onset of clinical disease in the spongiform encephalopathies.
